Sign inJoin waitlistJoin the waitlist

Nizar Tannir

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2000
Muhlenberg Hospital
1984–1985
Medical Oncology
1981–1984
American University Medical Center
1978–1980
Doctor of Medicine
1975–1979

Research

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2018 · 3,758 citations
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2015 · 999 citations
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
The Lancet Oncology · 2016 · 760 citations

Eric Jonasch
124 papers
Pavlos Msaouel
79 papers · 53 as a fellow
Surena Matin
64 papers
Jose Karam
61 papers · 2 as a fellow
Pheroze Tamboli
54 papers
Matthew Campbell
44 papers · 2 as a fellow
Amishi Shah
42 papers · 5 as a fellow
Priya Rao
38 papers
Toni Choueiri
38 papers
Jianjun Gao
37 papers · 1 as a fellow
CW
Christopher Wood
35 papers
KS
Kanishka Sircar
32 papers

Clinical trials

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2018–2025
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2007–2016
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2007–2015
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2005–2011